Table 2.
Remission and clinical variables in the tocilizumab-treated group of the SATORI study at week 24
| Variable | n (%) |
|---|---|
| DAS28-ESR < 2.6 (% of patients who participated in the full 24-week study) | 25 (47.2) |
| SJC in 28 joints = 0 in DAS remitters (% in DAS remitters) | 11 (44.0) |
| TJC in 28 joints = 0 in DAS remitters (% in DAS remitters) | 17 (68.0) |
| SJC + TJC in 28 joints ≤ 1 in DAS remitters (% in DAS remitters) | 12 (48.0) |
| CDAI < 2.8 (% of patients who participated in the full 24-week study) | 8 (15.1) |
| SJC in 28 joints = 0 in CDAI remitters (% in CDAI remitters) | 7 (87.5) |
| TJC in 28 joints = 0 in CDAI remitters (% in CDAI remitters) | 8 (100) |
| SJC + TJC in 28 joints ≤ 1 in CDAI remitters (% in CDAI remitters) | 7 (87.5) |
| SDAI < 3.3 (% of patients who participated in the full 24-week study) | 9 (17.0) |
| SJC in 28 joints = 0 in SDAI remitters (% in SDAI remitters) | 8 (88.9) |
| TJC in 28 joints = 0 in SDAI remitters (% in SDAI remitters) | 9 (100) |
| SJC + TJC in 28 joints ≤ 1 in SDAI remitters (% in SDAI remitters) | 8 (88.9) |
SJC swollen joint count, TJC tender joint count